Barclays analyst Matt Miksic maintains $Edwards Lifesciences (EW.US)$ with a buy rating, and maintains the target price at $85.
According to TipRanks data, the analyst has a success rate of 62.2% and a total average return of 7.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
Edwards Lifesciences reported a robust performance in sales and earnings, with the future outlook for Q4 and long-term projections up to 2025 anticipated to sustain the stock's upward trajectory.
The assessment is that it may require several more financial quarters for Edwards Lifesciences to assure investors of the stabilization of its TAVR franchise after the third-quarter report.
Expectations were subdued prior to the release of the quarterly results, and subsequent discussions regarding Q4 and future fiscal years did not dispel concerns of potential decline. Although the slowing Q4 TAVR trends are partially attributable to one-time factors, it remains challenging to counter the notion that TAVR growth may continue to decelerate in the upcoming fiscal year.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Matt Miksic維持$愛德華生命科學 (EW.US)$買入評級，維持目標價85美元。
根據TipRanks數據顯示，該分析師近一年總勝率為62.2%，總平均回報率為7.2%。
此外，綜合報道，$愛德華生命科學 (EW.US)$近期主要分析師觀點如下：
愛德華生命科學報告了銷售和收入方面的強勁表現，展望未來到2025年第四季度和長期預期都有望維持股價的上漲軌跡。
評估顯示，愛德華生命科學可能需要幾個更多的財政季度來讓投資者相信其TAVR業務在第三季度報告後的穩固性。
在發佈季度業績之前，市場對預期持謹慎態度，而關於第四季度和未來財政年度的討論並未消除對潛在下滑的擔憂。儘管第四季度TAVR趨勢減速部分歸因於一次性因素，但難以反駁TAVR增長可能會在未來財政年度繼續減速的觀點。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
